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Motivation. Multivariate analyses are advantageous for the simultaneous testing of the separate and combined eﬀects of many
variables and of their interactions. In factorial designs with many factors and/or levels, however, suﬃcient replication is often pro-
hibitively costly. Furthermore, complicated statements are often required for the biological interpretation of the higher-order inter-
actions determined by standard statistical techniques like analysis of variance.
Results. Because we are usually interested in ﬁnding factor-speciﬁc eﬀects or their interactions, we assumed that the observed
expression proﬁle of a gene is a manifestation of an underlying factor-speciﬁc generative pattern (FSGP) combined with noise. Thus,
a genetic algorithm was created to ﬁnd the nearest FSGP for each expression proﬁle. We then measured the distance between each
proﬁle and the corresponding nearest FSGP. Permutation testing for the distance measures successfully identiﬁed those genes with
statistically signiﬁcant proﬁles, thus yielding straightforward biological interpretations. Association networks of genes, drugs, and
cell lines were created as tripartite graphs, representing signiﬁcant and interpretable relations, by using a microarray experiment of
gastric-cancer cell lines with a factorial design and no replication. The proposed method may beneﬁt the combined analysis of het-
erogeneous expression data from the growing public repositories.
 2004 Elsevier Inc. All rights reserved.
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Factorial designs have advantages in eﬃciency,
power, and in the elegance of statistical testing [26].
Generalizations based on factorial experiments are
broader than those obtained from single variable exper-
iments, as the eﬀect of treatment is studied across diﬀer-
ent conditions.1532-0464/$ - see front matter  2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.jbi.2004.07.011
q Availability: http://www.snubi.org/software/FSGP/.
* Corresponding author. Fax: +82 2 747 4830.
E-mail address: kimx0519@tc.umn.edu (H. Kim).Replication is a cornerstone of scientiﬁc research. The
importance of replication in microarray experiments has
been highlighted as a means of increasing the precision
of estimated quantities and of providing information
about the uncertainties of estimates [16,19]. However,
we often have to deal with poorly replicated experimen-
tal datasets because of unwanted limitations in resource,
methodology, or knowledge.
DNA microarrays measure thousands of gene expres-
sion levels in a massively parallel way such that even a
single classical two-dye technique microarray
experiment may result in a reasonable estimation of sta-
tistical signiﬁcance and experimental quality control.
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expressed genes in a single-slide experiment has been
demonstrated by a method choosing cut-oﬀs in the dis-
tribution of ratios [7] and by a hierarchical Bayesian
model based on posterior odds change [22]. Methods
that determine diﬀerentially expressed genes using only
a few replicates have also been introduced [1,34].
Previous methods relying on comparisons of two or
more levels of a single factor, however, do not apply
to multivariate cases. One needs a method ﬂexible en-
ough to allow for complex experimental design. Analysis
of variance (ANOVA) is standard technique for analyz-
ing such multivariate datasets.
One experimental dilemma, however, concerns the
determination of the optimal number of replicates. In
a factorial design with many factors and/or levels, repli-
cation may often be prohibitively costly. For example, in
a 10 by 10, 2-factor 10-level experimental design, 100
microarray slides are needed with no replication. Even
simple triplication of the experiment, which may not
be suﬃcient, requires 200 more microarray slides.
Clearly, the disadvantages of such replication, given lim-
ited resources, is to lose the opportunity to systemati-
cally explore the high-dimensional problem space
enriched by many interesting factors that we want to
measure. For example, a multivariate analysis technique
requiring no replication may permit one to systemati-
cally explore 200 more factor levels (i.e., 10 · 20) using
a 10 by 30 experimental design with no replication.
Biological interpretability, its clarity and relevance
may be the most desired properties of a good micro-
array data analysis technique. However, biological
interpretability of the results of standard ANOVA-type
statistical methods may not be guaranteed in a facto-
rial design with many factors and levels because of
the large number of statistically signiﬁcant higher-order
interactions. As correctly pointed out by Pavlidis and
Noble [24], when more than two levels are present
for variables, ANOVA might indicate a signiﬁcant ef-
fect of a factor on expression, but does not determine
which factor levels show diﬀerent expression from
any others. Moreover, describing statistically signiﬁ-
cant higher-order interactions in a multifactorial exper-
iment typically requires an extremely complicated
statement.
With the growing number of microarray standards
such as MIAME (Minimum Information About a
Microarray Experiment, [4]) and MAGE-ML (Micro-
array Gene Expression Markup Language, [32]), and
of public expression-data repositories such as ArrayEx-
press [5] and GEO [9], we clearly require more powerful
analytical methods to discover the signiﬁcant and inter-
pretable patterns from large multifactorial microarray
data with poor or insuﬃcient replicates, to facilitate
the mining of a huge collection of microarray data from
heterogeneous sources.In this paper, we propose a procedure for identifying
genes that show both substantive and interpretable
gene-expression patterns in multifactorial microarray
experiments with no or poor replication. The proposed
method identiﬁes the optimal combination of biological
factor(s) explaining the expression proﬁle of the diﬀeren-
tially expressed genes. In eﬀect, we test all (biologically)
interpretable patterns from a multifactorial design, se-
lect the nearest pattern for each expression proﬁle, and
evaluate statistical signiﬁcance.
First, we deﬁne a factor-speciﬁc generative pattern
(FSGP, see method), which is readily interpretable,
and which represents all interpretable patterns enumer-
ated from the particular design involved. We deﬁne
the distance between a gene expression proﬁle and
FSGP, ﬁnd the FSGP nearest each genes expression
proﬁle, and measure the distance between each proﬁle
and the corresponding nearest FSGP. A Genetic Algo-
rithm (GA) is created to determine the FSGP nearest
a gene expression proﬁle. Finally, we determine the
FDR (false discovery rate)-corrected statistical signiﬁ-
cance of the distance by permutation testing.
The proposed procedure is illustrated using 54 cDNA
microarray experiments with two factors (i.e., six che-
motherapeutic agents and nine gastric cancer cell lines)
where the cancer cell lines are labeled before and after
a chemo-drug treatment. The procedure demonstrates
how to reliably identify genes with drug and/or cancer-
speciﬁc expression patterns, yielding straightforward
biological interpretations, for multifactorial microarray
data with poor replication.
This paper is organized as follows. In Section 2, we
deﬁne FSGP and describe a GA implementation de-
signed to ﬁnd the FSGP nearest a given expression pro-
ﬁle. Section 3.1 describes data preprocessing steps.
Section 3.2 describes our permutation scheme for the
strong control of type-I error. Genes identiﬁed by the
proposed method are listed and investigated in relation
to the associated drugs and cell lines. The association
networks of the genes, drugs, and cell lines are recon-
structed as tripartite graphs in Section 3.3, and this is
followed by a discussion in Section 4.2. Methods
2.1. Factor-speciﬁc generative patterns and pattern
distance
Suppose that there are N factors denoted by n
(=1, . . . ,N) and K levels for each factor denoted by kn
(=1n, . . . ,Kn), a typical experimental design for the mul-
tifactorial analysis involves Kn microarrays.
An expression proﬁle (or a pattern) of a gene can be
represented by an N-dimensional matrix with Kn cells
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illustrated in Fig. 1 (N = 2, K1 = 6, and K2 = 9).
Let fn be a particular level of factor n such that
fn 2 {1n, 2n, . . . ,Kn}. A pattern is deﬁned to be speciﬁc
to fn if all Ck1;...;kn1;fn;knþ1;...;kN are signiﬁcantly changed.
A factor-speciﬁc generative pattern, FSGP (ki,kj, . . .),
is deﬁned as a pattern that is speciﬁc to all ki,kj, . . . and
not to others. Therefore, there are in general 2
P
Kn
FSGPs for a microarray experiment with Kn slides.
As deﬁned above, an expression pattern in a multifac-
torial design is generally deﬁned as ‘‘speciﬁc’’ to one or
more factors if the expression levels of all cells related to
the factor(s) are all signiﬁcantly changed. For example,
the expression pattern in Fig. 1A is speciﬁc to the fac-
tors, t1, t2, t3, and t4, but not to others. Fig. 1C proﬁle
is speciﬁc to c2 and nearly speciﬁc to c6 and t3. Notice
that we use the term, factor, although level may be a
more precise term for multifactor design. We use the
term for convenience and to prevent possible confusion
between factor level and gene-expression level.
An FSGP is an expression pattern speciﬁc to a (com-
bination of) factor(s) (or more precisely, factor level(s)).
We view an observed expression proﬁle as a manifesta-
tion of the underlying FSGP combined with noise. For
example, we view that the expression proﬁle in Fig. 1B
is likely to be generated by the t3-speciﬁc generative pat-
tern, FSGP (t3), but has a pattern distance 1 from
FSGP (t3) because of intervening noise. The FSGPs de-
noted by FSGP (ai,bj, . . .) in Fig. 1 can also be repre-
sented by a list of bit patterns, as such the pattern in
Fig. 1C can be denoted as FSGP ((0,0,1,0,0,0),
(0,1,0,0,0,1,0,0,0)). Accordingly, there are in generalFig. 1. Gene expression proﬁles with measured pattern distances with
respect to the nearest factor-speciﬁc generative patterns. (A) t1, t2, t3, t4-
speciﬁc generative pattern (d = 0), (B) t3-speciﬁc generative pattern
(d = 1), (C) t3,c2,c6-speciﬁc generative pattern (d = 3), and (D) non-
speciﬁc pattern or non-pattern (d = 7). Pattern distance in the binary
space is simply the number of mismatches (i.e., the Hamming
distance). ci, the ith cell-line; ti, the ith anti-cancer drug.2
P
Kn FSGPs for a microarray experiment with Kn
slides.
We deﬁne the pattern distance of an expression pro-
ﬁle as the distance between the proﬁle and the nearest
FSGP. Thus, to measure the pattern distance of an
expression proﬁle, one ﬁrst has to ﬁnd its nearest FSGP.
Section 2.2 demonstrates how to ﬁnd the FSGP nearest
a proﬁle by implementing a GA. For the purpose of
illustration, we ﬁrst demonstrate the pattern distance
in binary space and then generalize it.
The pattern distance is deﬁned as (a kind of) Ham-
ming distance between an expression proﬁle and its
nearest FSGP. In the binary space, where the expression
level is dichotomized to zero (i.e., non-changed and de-
picted as blank cells) or one (i.e., signiﬁcantly changed
and depicted as dark cells), pattern distance simply
equals the number of mismatches (Fig. 1). Therefore,
the pattern distance between a two-factor proﬁle Cij
and the nearest FSGP, C0ij, equals
P jCij  C0ijj. More
generally, the N-dimensional pattern distance of
Ck1;...;kN equals
P jCk1;...;kN  C0k1;...;kN j.
Fig. 1A demonstrates a case in which the nearest
FSGP perfectly matches the observed expression proﬁle,
as such the pattern distance equals to zero. Fig. 1B
exhibits an expression proﬁle with one mismatch
(FSGP (t3),d = 1) and (C) one with three mismatches
(FSGP (t3, c2, c6), d = 3). Moreover, a proﬁles nearest
FSGP can be the null-pattern, FSGP (), as shown in
Fig. 1D. Because we are interested in search for distinct
patterns rather than a null-pattern, the distributions of
pattern distances from the null-pattern is estimated sep-
arately and treated in the manner described in Section
3.2. The signiﬁcance of the nearest FSGP obtained can
be determined reliably by using the permutation test de-
scribed in Section 3.2.
Generalization to non-binary space can easily be
achieved by setting the range of expression levels in cells.
For example, if the range of the expression level is .0–1.0
and the dark cell represents .9 and the blank cell .1 in
Fig. 1B, then, because the FSGP (t3) should ideally have
ideal value of 1.0 for the cells in the third row (t3) and 0
for those in the extra rows, the pattern distance of Fig.
1B proﬁle can be calculated as follows: {|1.0  .9|
* 8 + |1.0  .1| * 1} + {|.0  .1| * (9(columns) *5(rows))}
= .8 + .9 + 4.5 = 6.2. GAs for both binary and non-bi-
nary conditions are available at http://www.snubi.org/
software/FSGP/.
2.2. Genetic algorithm used to ﬁnd the nearest generative
pattern
The GA is a non-deterministic optimization proce-
dure based on a massively parallel search [14], where
each potential solution to a problem is represented in
the form of a string (or a chromosome) with encoded
parameters (or attributes). A series of random strings
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solution space and then evolve towards ﬁtness by muta-
tion, mating, and crossover. The selection process ap-
plies a ﬁtness function to measure the goodness of ﬁt
to select the next generation population. The Boltzmann
probability distribution may also be applied to aﬀect
acceptance or rejection based on an analogy to the sto-
chastic free energy optimization.
To ﬁnd the nearest FSGP of an observed gene expres-
sion proﬁle, a simple GA was created using a classical
binary ﬁxed-string representation [11] for factor-speciﬁc
eﬀects. Factors (N) were represented as chromosomes
whose lengths equaled the corresponding number of lev-
els (Kn). For example, the nearest FSGP for the Fig. 1B
proﬁle is represented as (0,0,1,0,0,0) in chromosome 1
and as (0,0,0,0,0,0,0,0,0) in chromosome 2, represent-
ing drug- and cell-line speciﬁc eﬀects, respectively. The
nearest FSGP for the Fig. 1C proﬁle is represented as
((0,0,1,0,0,0),(0,1,0,0,0,1,0,0,0)). Therefore, the solu-
tion space has the size of 26+9 FSGPs. The chromosomal
representation can easily be scaled up to more than two
factors and to many levels with 2
P
Kn FSGPs. Both the
binary and the non-binary (i.e., continuous-value) pat-
tern distances described in Section 2.1 can be applied
as measures of goodness of ﬁt. Fairly standard imple-
mentation of GA with mutation, mating and crossover
successfully identiﬁed the nearest FSGP for each expres-
sion proﬁle used. A GA implementation for user evalu-
ation with adjustable parameters written in the Python
programming language is available at http://www.
snubi.org/software/FSGP/.3. Results
3.1. Data set and normalization
A data set from gastric-cancer research was studied.
The primary goal of the study was to explore the poten-
tial gene-drug interactions in a search for novel drug tar-
gets. DNA microarray slides were prepared containing
2400 fully annotated genes. Six chemotherapeutic agents
were administered to nine gastric-cancer cell lines,
resulting in 54 experiments. A classical two-dye tech-
nique with Cy5 and Cy3 ﬂuorescent dyes was applied be-
fore (Cy3) and after (Cy5) anti-cancer drug treatment.
Variance stabilizing normalization by Huber et al.
[15] was applied with the vsn package in Bioconductor
using the R statistical package. After performing inten-
sity-dependent global LOWESS regression, spatial and
intensity-dependent eﬀects were managed by pin-group
LOWESS normalization, and this was followed by
applying the approach described by Yang et al. [35].
For the purpose of illustration, we assigned dummy
binary values to the data by applying six cut-oﬀ levels
(i.e., 5, 10, 15, 20, 25, and 30%) and three-directiongroups (i.e., up, down, or up-or-down regulated
groups). For example, we assigned 1s to the highest
5% and 0s to the others when we applied a 5% cut-oﬀ
level. Overall, we created 18 dichotomized data sets
(i.e., six cutoﬀs by three directions), which described
the expression proﬁles of 2400 genes under 54
conditions.
3.2. Permutation test and false discovery rate
To perform formal statistical testing, we wanted to
estimate the null distribution(s) for the proposed statis-
tic, the pattern distance deﬁned in Section 2.1. When
scoring thousands of gene expression proﬁles simulta-
neously, we also had to deal with the problem of ‘‘multi-
ple hypothesis testing.’’ Two types of error
measurements are commonly used in multiple-hypothe-
sis testing: FWER (family wise error rate) and FDR
(false discovery rate). FWER oﬀers a very strict error
measure of at least one false positive result among all
signiﬁcant hypotheses. FDR [2,33] is deﬁned as the ex-
pected proportion of false positive results among all re-
jected hypotheses multiplied by the probability of
making at least one rejection. FDR oﬀers a much less
strict criterion, which hence leads to an increase in statis-
tical power. Genes with pattern distances greater than a
threshold are considered potentially signiﬁcant. The per-
centage of such genes identiﬁed by chance is the false
discovery rate (FDR). We applied permutation test that
does not require any distributional assumptions.
We ran ca. ﬁve million permutations of the 54 sample
labels in the present study. It is possible to reduce the
number of permutations by testing for all possible cate-
gories. For example, the permutation results are the
same expression proﬁles having the same number of sig-
niﬁcant cells, i.e., the cells with 1s in the matrix. Thus,
there are only 55 conditions (i.e., 0–54 1s in the six-
by-nine matrix) requiring permutation. By permuting
the 54 sample labels 105 times for the 55 groups and
by applying GA to ﬁnd the nearest FSGP for each gene,
we ran the GA implementation over ca. 3 days using 18-
nodes of a Linux cluster system. It should be noted that
the illustration used in our study could be extended to
more general cases with unbalanced factors and levels.
Users may ﬂexibly extend the proposed method for dif-
ferent data sets, and the number of testing permutations
can be greatly reduced by excluding the null-pattern
groups.
To estimate the FDR, the proportion of falsely signif-
icant expression proﬁles corresponding to the expression
proﬁle of each gene were computed by counting the num-
ber of permuted proﬁles showing equal or smaller pattern
distances (to the corresponding nearest FSGP) than that
of the observed (i.e., non-permuted) proﬁle. The thresh-
old can be adjusted to identify smaller or larger sets of
proﬁles, and the FDRs are calculated for each set (Fig. 2).
Fig. 4. Estimated FDRs across six cut-oﬀ and at all pattern-distance
levels in the (A) up-or-down, (B) up, and (C) down regulated
groups.
Fig. 2. Distribution of estimated FDR (false discovery rate). By
permuting the sample labels, estimated distributions of FDRs were
obtained across all levels of pattern distances and diﬀerent six cut-oﬀ
levels in the up-or-down regulated group. The other two groups
showed the same pattern (data not shown).
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mated by averaging the number of falsely signiﬁcant
expression proﬁles at each pattern distance level.
Fig. 2 shows the estimated FDRs at all levels of pattern
distance for six diﬀerent cutoﬀs in the up-or-down reg-
ulated group. The other two directional groups exhib-
ited the same pattern (data not shown). For the
purpose of illustration, the frequency and FDR (±SD)
plots are overlapped with those of the up-or-down reg-
ulated group at six cutoﬀs in Fig. 3. The other two direc-
tional groups showed the same pattern (data not
shown). Fig. 4 demonstrates the distributions of the esti-
mated FDRs at all pattern-distance levels across six cut-
oﬀs in the three directional groups. It seems that about
5% of the FDR can be obtained by applying a threshold
of pattern distance, d = 5, for the six cutoﬀs.
3.3. Genes showing drug and cell-line speciﬁc patterns
For illustration purposes, the (two tailed) up-or-
down regulated group at the 10% cut-oﬀ level, which
may be the most biologically relevant, was selected for
further investigation. Thirty-seven genes were deter-Fig. 3. Estimated FDRs (mean ± SD). Estimated FDRs of the up-or-
down regulated group are overlapped by the corresponding frequency
histograms at all levels of pattern distance and at six cut-oﬀ levels, 5,
10, 15, 20, 25, and 30%.mined to be signiﬁcant after applying strict control of
the type-I error at FDR < 0.025, according to the pro-
posed method (Table 1). We identiﬁed 17 more genes
at FDR < 0.05.
It is worth noting that the proposed method reduces
the eﬀect of higher-order interactions from a multiplica-
tive (Kn, i.e., an eﬀect of N factors on an expression le-
vel) down to an additive (
P
Kn, i.e., an eﬀect of a factor
on an expression proﬁle) complexity, given the assump-
tion that the factors independently aﬀect gene expression
level. By doing so, it greatly improves the interpretabil-
ity of the analysis by permitting us to reconstruct an
(N + 1)-partite-graph of the whole association network,
which is equivalent to the set of dyadic associations
identiﬁed as in Table 1.
k-Partite graph is a set of graph vertices decomposed
into k disjoint sets such that no N graph vertices within
the same set are adjacent. One can easily construct a tri-
partite graph by simply combining the dyadic associa-
tions among the three types of vertices, i.e., genes,
drugs, and cell lines, described in Table 1.
Fig. 5 exhibits the tripartite-graph representation of
the association network for the signiﬁcant 54 genes, six
drugs, and nine cell lines (FDR < 0.05) identiﬁed by
the proposed method. Genes and associations having
FDR < 0.025 are represented by bold characters and
bold lines and those having FDR < 0.05 by italic charac-
ters and thin lines. Among the 37 genes at FDR < 0.05,
12 genes demonstrated a single drug-speciﬁc eﬀect, 20
genes a single cell-line eﬀect, three genes a dual cell-line
eﬀect, and two genes showed both drug and cell-line ef-
fects (Table 1 and Fig. 5).
Doxorubicin, an anthracycline antibiotic produced
by the fungus Streptomyces peucetius, was found to spe-
ciﬁcally eﬀect the MHC class I HLA-C-a-2 chain, the
HLA class I locus C heavy chain, the immunoglobulin
j light chain and the interferon-inducible protein
(IFI616, G1P3). Interestingly, all genes related to the
anthracycline antibiotic were immune-response-related
genes. Moreover, interferon a has been shown to modify
the anti-tumor eﬀect of doxorubicin and reduce bladder-
Table 1
List of genes showing cancer and/or drug-speciﬁc eﬀects and the pattern distance, FDR (false discovery rate), and the number of cells signiﬁcantly
changed for each gene expression proﬁle
Gene description d Noa (=n) Drug eﬀect Cell-line eﬀect
Nuclear aconitase mRNA, encoding mitochondrial 3 (6) CPT-11
Transcription factor ZFM1 isoform B3. SF1: splicing factor 1 3 (3) SNU601
a-2-Macroglobulin 4 (6) SNU601
Immunoglobulin j light chain 4 (7) Doxorubicin
Ferritin heavy chain 4 (6) SNU1
Serine protease (Omi). PRSS25, protease, serine, 25 4 (6) SNU620
Cytochrome b5. NQO1: NAD(P)H dehydrogenase, quinone 1 5 (7) AGS
DNA polymerase epsilon, catalytic polype 5 (7) SNU216
MAPK6: mitogen activated PK 6. (ERK3 protein kinase.) 5 (6) Cisplatin
Farnesyltransferase a-subunit 5 (7) M1
RNA for c-fes. FES: felin sarcoma oncogene 5 (7) M1
X-box binding protein-1 (XBP-1) 5 (7) AGS
FABP5: Fatty acid binding protein homologue (psoriasis associated) 5 (7) M74
GDNF family receptor a 2 (GFRA2) 5 (7) M74
Zinc ﬁnger protein FPM315 (ZNF263) 5 (7) SNU668
Putative src-like adapter protein (SLAP) 5 (7) SNU620
Pyrroline 5-carboxylate reductase 6 (12) AGS, SNU1
Rohu mRNA for rhodanese (HSROHU) 6 (9) Cisplatin
mRNA for APRIL protein. Acidic protein rich in leucines 6 (8) AGS
Glutathione peroxidase (GPX1) 6 (8) AGS
mRNA for P1cdc47. MCM7 minichromosome maintenance deﬁcient 7 6 (8) SNU601
(clone PWHCLC2-8) cardiac myosin light chain 2 6 (8) SNU668
rhoGAP protein 6 (8) M74
Human MHC class I HLA-C-a-2 chain and alternative mRNA 6 (7) Doxorubicin
UBE3A:ubiquitin prot. Ligase E3A (HPV E6-asso prot., Angelman synd) 6 (7) Taxol
KIAA0406 6 (7) Taxol
mRNA for Pr22 protein. STMN1: stethmin 1/onprotein 18 6 (8) SNU601
LAMA2: laminin, a 2 (merosin, congenital muscular dystrophy) M chain 7 (13) SNU620,SNU1
mRNA for KIAA0385 gene 7 (9) SNU620
Human mRNA for HLA class I locus C heavy chain 7 (8) Doxorubicin
Ras-related protein (Krev-1). RAP1A: RAP1A, member of RAS oncogene family 7 (8) Cisplatin
mRNA for KIAA0288 gene 7 (7) M74, SNU1
Myo-inositol monophosphatase 2 8 (11) CPT-11
SLC1A4: solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 8 (12) Taxol, M1
SLC16A3: solute carrier family 16 (MCT3, Monocarboxylate transporters), member 3 9 (14) TSA, SNU601,SNU620
G1P3: interferon, a-inducible protein (cDNA, IFI616) 10 (15) Doxorubicin
CDC2: cell division cycle 2, G1 to S and G2 to M 10 (13) 5-FU
a Number of the cells showing signiﬁcantly changed expression levels.
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by intercalating the anthracycline portion, chelating me-
tal ions, generating free radicals or by inhibiting DNA
topoisomerase II.
MAPK6, Rohu, and Rap1 showed cisplatin-speciﬁc
eﬀects. The platinum drug, cisplatin, is a cell-cycle
non-speciﬁc anti-cancer drug, which binds to DNA
and causes the production of intrastrand cross-links
and DNA adduct formation. Cisplatin treatment acti-
vates multiple signal transduction pathways, which can
lead to several cellular responses, including cell cycle ar-
rest, DNA repair, survival or apoptosis. Moreover,
genotoxic stress induces multiple signal transduction
pathways, which include the MAP kinase pathways
[8,13,20,28]. The same pathways are also related to plat-
inum drug resistance [25]. Rohu mRNA for rhodanese
(mercaptopyruvate sulfurtransferase) catalyzes the
transfer of a sulfur ion to cyanide during cyanide degra-dation. Platinum cyanide binds at the entrance of the ac-
tive site pocket, involving Arg-186 and Lys-249 of
rhodanese [21]. Although we were unable to ﬁnd a re-
port on the interaction between cisplatin and Rap1,
the latter, a ras-related gene with transformation sup-
pressor activity, is closely associated with the MAP ki-
nase cascades [3,6,17,30,36].
Taxol (paclitaxel) binds to the tubulin heterodimer,
hence preventing microtubules from disassembling
and cells from dividing. A taxol-speciﬁc eﬀect was
found in ubiquitin protein ligase E3A, KIAA0406,
and SLC1A4 (neutral amino acid transporter). An
inhibitor or ubiquitin-dependent multicatalytic protease
complex (proteasome) was shown to be cytotoxic to
human myeloid leukemia cell lines, and pre-treating
this inhibitor enhanced the cytotoxicities of taxol and
cisplatin [31]. Parkin, a protein–ubiquitin E3 ligase,
was found to be tightly bound to microtubules in
Fig. 5. Tripartite-graph representation of gene, drug, and cell-line
association networks. Factor-speciﬁc generative patterns signiﬁcantly
associated to genes were determined and used for the reconstruction of
the tripartite-graph networks.
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Although we could not ﬁnd a report on the interaction
between SLC1A4 and taxol, multidrug transporters
have been suggested to be involved in chemotherapeu-
tic-drug resistance [10,12,29]. Moreover, TSA (Trichos-
tatin A) has been related to another transporter
protein, SLC16A3. Interestingly, both of these trans-
porters showed multiple drug-and-cancer-speciﬁc eﬀects
(i.e., Taxol and M1 vs. TSA and SNU601 and
SNU620). KIAA0406 is a gene of unknown function.5-Fluorouracil (5-FU) produced only one gene-spe-
ciﬁc eﬀect on Cdc2 kinase. Cdc2 kinase forms a complex
with B-type cyclins, which are central regulators of the
progression from G2 to mitosis. Moreover, cyclin B lev-
els following the treatment of a HepG2 hepatic cancer
cell line with 5-FU or methotrexate were shown to be
down regulated, and this cyclin B down-regulation was
suggested as a means of regulating G2 arrest [18].4. Discussion
We propose a method for identifying the optimal
combination of biological factor(s) explaining the
expression proﬁle of the diﬀerentially expressed genes
in a microarray experiment. The method outperforms
when compared to typical multifactorial analysis such
as ANOVA in two ways: reducing the higher-order
interactions from a multiplicative to an additive com-
plexity and, more importantly, no replicates are
required.
Although suﬃcient replication is desirable whenever
possible, the replication of microarray experiments
may often be prohibitively costly. A balance must be
found between the increased number of replicates and
a reduction in the number of factors to be evaluated.
Moreover, with increasing standardization [4,32] and
growth of public repositories of expression data [5,9],
it becomes important that powerful methods are devel-
oped to identify useful patterns from among the huge
collections in heterogeneous expression databases.
In this study, genes speciﬁcally associated with drugs
and/or cancers were successfully identiﬁed. We as-
sumed that each observed expression proﬁle was cre-
ated by the underlying FSGP and noise, and devised
a GA to determine the nearest FSGP to each expres-
sion proﬁle and then measured the pattern distance
of the proﬁle with respect to the nearest FSGP. Final-
ly, a statistical signiﬁcance score was assigned using a
permutation test.
One challenge presented by experiment with cancer
cell-lines is that, because of cell-line heterogeneity, the
in vitro eﬀects observed do not accurately reﬂect the in
vivo or clinical condition. The result of the proposed
method, when it suggests a drug-speciﬁc eﬀect, implies
that the identiﬁed gene may consistently interact with
the drug across many diﬀerent cell lines. Thus, the tech-
nique suggests a more robust generalizability with re-
spect to the cell-line heterogeneity such that it is more
likely that the identiﬁed gene may also interact with real
human cancer cells in vivo.
One property of the proposed method is that the
nearest expression proﬁle pattern provides a straightfor-
ward biological interpretation. High-biological inter-
pretability becomes even more important when many
factors and/or analysis levels are involved, when the
J.H. Kim et al. / Journal of Biomedical Informatics 37 (2004) 260–268 267interpretation of higher-order interactions of factors can
be extremely complicated. The proposed method can be
viewed as a feature selection method augmented by sta-
tistical signiﬁcance scoring. Extracted features may also
be easily added to the analysis. Here we applied (a kind
of) Hamming distance as a measure of pattern distance;
however, one may ﬂexibly choose an alternative appro-
priate distance metric.
In the present study, for the purpose of illustration,
we applied a fairly standard GA with ﬁxed chromo-
somal representation to explore the relatively small
26+9 FSGP search space. The actual implementation or
the performance of the GA itself is not the main issue
in the present study. Rather, one can apply the proposed
scheme of the present study of deﬁning a pattern dis-
tance, devising a search algorithm to ﬁnd the nearest
FSGP, and evaluating the statistical signiﬁcance. Other
meta-heuristic methods like simulated annealing and
Tabu search may also be successfully applied.
Association networks among genes, drugs, and cell
lines were reconstructed from the identiﬁed FSGPs
and showed signiﬁcant associations with the observed
gene expression proﬁles. The tripartite graphs in Fig. 5
can completely capture relevant multifactorial experi-
mental information. In general, using the proposed
method, the association networks of N factorial experi-
ments can be represented as (N + 1)-partite graphs.
In contrast to traditional statistical test like ANOVA,
which informs us of the statistical signiﬁcance of a given
null hypothesis, the nearest generative pattern of an
expression proﬁle informs us of the most likely underly-
ing FSGP of the proﬁle. However, the proposed method
does not test all possible hypotheses. Rather it directly
ﬁnds the best explanatory model and tests the statistical
signiﬁcance of the model using a permutation test.
Therefore, it should be noted that our result does not
necessarily exclude the statistical signiﬁcances of
remaining hypotheses. For example, the second or the
third nearest generative pattern of an expression proﬁle
may also be statistically signiﬁcant given the same FDR
threshold. It is trivial to extend the method to test the
signiﬁcances of all competing hypotheses. When we
search only for the nearest generative pattern, the prop-
er interpretation of the result is that the expression pro-
ﬁle of gene x in an experimental setting y can be best
explained by (the list of) factor(s), zn.
A microarray experiment can be regarded as a data-
driven method of massive hypothesis generation. For
each hypothesis generated, whether positive or negative,
we tried to ﬁnd related publications. Although there are
more than one million publications in PubMed, a micro-
array experiment with a multifactorial design generally
addresses such a huge problem space (i.e., 157,286,
400 = 26+91 (factors) · 2400(genes) in the present
study) that it is literally impossible to ﬁnd at least one
report corresponding to the associations tested. Itseemed that pre-genomic studies have explored the
problem space only sparsely.Acknowledgment
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